Investor Type | Firm |
Industries | BioTech • Businesses Solutions • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Life Science • Pharmaceutical (& Medicine) |
Stages | Early, Seed, Series A, Series B |
Investing | United States |
Investment Range | $20,000,000 - $30,000,000 |
Investment Sweet Spot | $25,000,000 |
venBio is a life sciences investment firm established in 2011, dedicated to partnering with industry leaders to build transformative drugs and technologies in the life sciences sector. The firm, based in San Francisco with an additional office in Seattle, has nearly $1.1 billion in committed capital and invests in biotech, businesses solutions, HealthTech, medical devices, healthcare, life science, and pharmaceutical sectors with investments ranging from $20 to $30 million, aiming for a sweet spot of around $25 million. They focus on various stages of company development including early, seed, Series A, and Series B ventures. At the core of venBio's investment approach is a commitment to fund companies that pursue novel therapeutics aimed at unmet medical needs, ensuring that these companies are ideally positioned to achieve success. They are particularly meticulous about potential acquisition partners from inception, considering aspects such as intellectual property, chemistry, manufacturing, and the clinical trials' specifics including indication, trial design, endpoints, powering, and regulatory aspects. venBio's team expertise facilitates their portfolio companies in making a significant impact, fostering impactful and long-lasting relationships with the leaders they partner with. Overall, venBio's mission emphasizes support for teams developing treatments that make a significant difference in patient care, providing strategic guidance on the best development plans to advance these therapies to the marketplace.